Milestone Pharmaceuticals (NASDAQ:MIST) Insider David Bharucha Sells 12,245 Shares

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insider David Bharucha sold 12,245 shares of the firm’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $1.93, for a total value of $23,632.85. Following the sale, the insider owned 99,848 shares of the company’s stock, valued at $192,706.64. The trade was a 10.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

David Bharucha also recently made the following trade(s):

• On Monday, December 15th, David Bharucha sold 58,007 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.32, for a total value of $134,576.24.

Milestone Pharmaceuticals Price Performance

NASDAQ MIST opened at $1.94 on Thursday. The company has a debt-to-equity ratio of 2.74, a current ratio of 8.24 and a quick ratio of 8.24. The firm has a market capitalization of $165.23 million, a price-to-earnings ratio of -2.37 and a beta of 0.44. The company has a 50 day simple moving average of $2.23 and a 200-day simple moving average of $1.96. Milestone Pharmaceuticals Inc. has a 52-week low of $0.63 and a 52-week high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.05. Equities research analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Wells Fargo & Company upped their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. October Effect Ltd bought a new position in shares of Milestone Pharmaceuticals in the fourth quarter valued at approximately $105,000. SG Americas Securities LLC acquired a new position in Milestone Pharmaceuticals in the 4th quarter valued at $197,000. Bay Rivers Group raised its holdings in Milestone Pharmaceuticals by 72.9% in the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after acquiring an additional 12,170 shares during the period. Millennium Management LLC acquired a new position in Milestone Pharmaceuticals during the 3rd quarter worth $803,000. Finally, Boxer Capital Management LLC bought a new stake in Milestone Pharmaceuticals during the third quarter valued at about $1,333,000. Institutional investors own 86.18% of the company’s stock.

Key Milestone Pharmaceuticals News

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short?term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50?day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.